- Cardiologie
- Gastro-enterologie
- Hematologie
- Neurochirurgie
- Neurologie
- Oncologie
- Pediatrie
- Pijnkliniek
- Pneumologie
- Psychiatrie
- Reumatologie
- Urologie
- Uro-oncologie
Cardiologie
Studies
SCAD: A registry of Spontaneous coronary artery dissection (SCAD)
Arts: dr. Voet
CARDURION-1: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Arts: dr. Delens
CARDURION-2: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Arts: dr. Delens
Studiecoördinatoren
Lise Vermeir: lise.vermeir@vitaz.be
Gastro-enterologie
Studies
NATIV3: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
Arts: Prof. Dr. Schouten
TAK-062-2001: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
Arts: Dr. Holvoet
M21-446: A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects
with moderate to severe ulcerative colitis
Arts: Dr. Holvoet
SOPRANO: Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis
Arts: Dr. Holvoet
POMEROL: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation
Arts: Dr. Holvoet
HYRISS: A multicenter, international, prospective, non-interventional, observational study, to assess treatment retention of an adalimumab biosimilar (Hyrimoz®) in IBD patients in real life setting
Arts: Dr. Holvoet
M23-703: A Multicenter, Randomized study to Evaluate the safety and Efficacy of Lutikizumab for lnduction and Maintenance Therapy in subjects with Moderately to severely Active Ulcerative colitis
Arts: Dr. Holvoet
Vectors: An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease
Arts: Dr. Holvoet
AMARETTO: Subcutaneous infliximab after a previous intravenous dose optimization
Arts: Dr. Holvoet
CRYOPEN: Efficacy of cryotherapy by N20 (CryoPen®) in acute and chronic anal fissures
Arts: Dr. Ruymbeke
Studiecoördinatoren
Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be
Lise Vermeir: lise.vermeir@vitaz.be
Hematologie
Studies
LOXO-BTK-20030: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Arts: Prof. Dr. Van Hende
CA057-001: A Phase 3, Randomized, Multicenter, Open-Label Study, Comparing CC-92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Arts: Dr. Vande Broek
GCT3013-06: A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Assess the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) Plus Lenalidomide or Epcoritamab Alone as First-line Therapy in Anthracycline Ineligible Subjects With Diffuse Large B-cell Lymphoma
Arts: Prof. Dr. Van Hende
Monumental-06: A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Arts: Dr. Vande Broek
OLYMPIA 2: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETYOF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA
Arts: Prof. Dr. Van Hende
Studiecoördinatoren
Veerle De Corte: veerle.decorte@vitaz.be
Veerle De Hauwere: veerle.dehauwere@vitaz.be
Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be
Jenas Stevenheydens: jenas.stevenheydens@vitaz.be
Isabel De Brabander: isabel.debrabander@vitaz.be
Neurochirurgie
SABR-MESCC: Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC)
Arts: Prof. Dr. Van De Kelft
Studiecoördinatoren
Sophie Traen: sophie.traen@vitaz.be
Neurologie
OCEANIC STROKE: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an
acute non-cardioembolic ischemic stroke or high-risk TIA
Arts: Dr. Siau
Studiecoördinatoren
Lise Vermeir: lise.vermeir@vitaz.be
Oncologie
Studies
REMOTE: Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies
Arts: Dr. Lamot
Oncologie - borstkanker
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
Arts: Dr. Deleu
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Arts: Dr. Deleu
TROPION-BREAST-03: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy
Arts: Dr. Deleu
VIKTORIA-1: A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Arts: Dr. Everaert
Destiny Breast Respond: A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy
Arts: Dr. Deleu
ELEVATE: A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer
Arts: Prof. Dr. Kruse
Oncologie - Dermatologie
Retrospectieve evaluatie van de werkzaamheid en veiligheid van Cemiplimab voor gevorder cutaan squameus celcarcinoma binnen het Belgisch early access programma
Arts: Prof. Dr. Kruse
Oncologie - melanoma
REGENERON-2: A Phase 3 Trial of Fianlimab (Anti-Lag-3) And Cemiplimab Versus Pembrolizumab in the Adjuvant Setting In Patients With Completely Resected High-Risk Melanoma
Arts: Dr. Deleu
REGENERON-1: A PHASE 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or metastatic Melanoma
Arts: Dr. Deleu
Oncologie - hoofd-hals tumoren
AVEO: Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
Arts: Dr. Lybaert
STELLAR: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Arts: Dr. Lybaert
PROLONG: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study
Arts: Dr. Lybaert
Studiecoördinatoren
Veerle De Corte: veerle.decorte@vitaz.be
Veerle De Hauwere: veerle.dehauwere@vitaz.be
Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be
Jenas Stevenheydens: jenas.stevenheydens@vitaz.be
Isabel De Brabander: isabel.debrabander@vitaz.be
Pediatrie
Studies
RSV-Comnet-III: Disease Burden of RSV in Young Children in Primary Care
Arts: Dr. Vanlede
Studiecoördinatoren
Anske Van Den Abbeele: anske.vandenabbeele@vitaz.be
Pijnkliniek
Studies
BONS: Bilateral Occipital Nerve Field Stimulation for the prophylactic treatment of Difficult-to-treat Chronic Cluster Headache
Arts: Prof. Dr. Van Buyten
ANKERSTIM: Physician initiated database ‘Custom ONS Lead Model 09078’ van Medtronic
Arts: Prof. Dr. Van Buyten
DETECT: Differential targEt mulTiplexEd spinal Cord stimulation: a multicenter cohorT study
Arts: Prof. Dr. Van Buyten
OPERA: Objectifying performance assessments and personalized rehabilitation trajectories to improve return to work in patients with Persistent Spinal Pain Syndrome Type II: a randomized controlled trial.
Arts: Prof. Dr. Van Buyten
Product Surveillance Registry (PSR) NEUROLOGY PSTM EMEA INCEPTIV™ cohort
Arts: Dr. Smet
EU-DETECT: Open and closed loop Differential Target Multiplexed spinal cord stimulation in patients with persistent spinal pain syndrome type II: a European study protocol for a 12-month multicenter cohort study (EU-DETECT)
Arts: Dr. Smet
Studiecoördinatoren
Marieke Devos: marieke.devos@vitaz.be
Pneumologie
Studies
PACIFIC- 8: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)
Arts: Dr. Deschepper
SAFFRON: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Arts: Dr. Van De Kerckhove
TROPION-LUNG-07: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS 50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Arts: Dr. Deschepper
TROPION-LUNG-08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)
Arts: Dr. Deschepper
MOMENT: Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations MOMENT (Met nOn sMall cEll caNcer regisTry)
Arts: Dr. Deschepper
IMMUNO-MESODEC: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma
V940-002: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Arts: Dr. Deschepper
MK2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery
Arts: Dr. Deschepper
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Arts: Dr. Deschepper
eVOLVE-Meso: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma
Arts: Dr. Deschepper
M18-868: Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Arts: Dr. Deschepper
BO45217: A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated kras G12C-positive advanced or metastatic non-small cell lung cancer.
Arts: Dr. Deschepper
Studiecoördinatoren
Kirsten Van Camp: kirsten.vancamp@vitaz.be
Aurelie De Vos: aurelie.devos@vitaz.be
Psychiatrie
Studies
VENTURA5: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
Arts: Dr. De Weirdt
Studiecoördinatoren
Sophie Traen: sophie.traen@vitaz.be
Reumatologie
Studies
SPEAK: spondyloarthritis (psoriatic arthritis and axial spondyloarthritis) patient-centered experience initiating Bimekizumab in routine clinical practice: a multicountry, prospective, observational study
Arts: Dr. De Wilde
Studiecoördinatoren
Lise Vermeir: lise.vermeir@vitaz.be
Urologie
Studies
Thunder: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Arts: Dr. De Troyer
ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer (mCRPC)
Arts: Dr. De Troyer
Moonrise: TAR-210 Versus Single Agent Intravesical Chemotherapy in Participants With FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC)
Arts: Dr. De Troyer
Studiecoördinatoren
Sophie Traen: sophie.traen@vitaz.be
Uro-oncologie
Studies
CORPORA: CheckpOint inhibition in advanced uRothelial carcinoma: PredictiOn of response through RNA profiling (CORPORA)
Arts: Dr. Everaert
Studiecoördinatoren
Veerle De Corte: veerle.decorte@vitaz.be
Veerle De Hauwere: veerle.dehauwere@vitaz.be
Luna Van Hoyweghen: luna.vanhoyweghen@vitaz.be
Jenas Stevenheydens: jenas.stevenheydens@vitaz.be
Isabel De Brabander: isabel.debrabander@vitaz.be
